antiAll Cancer Research Results

antiAll, antiallergic: Click to Expand ⟱
Source:
Type:

Antiallergic Activity - Suppression of Allergic Responses

Type: Therapeutic effect / immune phenotype / functional outcome

Function: Antiallergic activity refers to suppression of allergic sensitization, mast-cell or basophil activation, IgE-mediated signaling, eosinophilic inflammation, histamine and leukotriene release, airway inflammation, or other manifestations of hypersensitivity.

Asthma: ↓ Allergic response is favorable. Increased antiallergic activity corresponds to reduced IgE/FcεRI signaling, mast-cell degranulation, eosinophil recruitment, type-2 cytokine signaling, mucus production, bronchoconstriction, and airway hyperresponsiveness.

Favorable Direction: ↑ Antiallergic activity = beneficial.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
8148- lamb,    Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells
- in-vitro, Pca, LNCaP
*antiAll↑, *Bacteria↓, AR↓, PSA↓, TumCCA↑, CDK4↓, CDK6↓, cycD1/CCND1↓, P53↑, P21↑, p27/CDKN1B↓, Apoptosis↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   cl‑Casp3↑, 1,   cl‑Casp9↑, 1,   p27/CDKN1B↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

PSA↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   PSA↓, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiAll↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: antiAll, antiallergic
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1745  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page